JP2013508392A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013508392A5 JP2013508392A5 JP2012535347A JP2012535347A JP2013508392A5 JP 2013508392 A5 JP2013508392 A5 JP 2013508392A5 JP 2012535347 A JP2012535347 A JP 2012535347A JP 2012535347 A JP2012535347 A JP 2012535347A JP 2013508392 A5 JP2013508392 A5 JP 2013508392A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- regimen
- days
- day
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012634 fragment Substances 0.000 claims 40
- 239000008194 pharmaceutical composition Substances 0.000 claims 40
- 210000001744 T-lymphocyte Anatomy 0.000 claims 25
- 239000000427 antigen Substances 0.000 claims 9
- 102000036639 antigens Human genes 0.000 claims 9
- 108091007433 antigens Proteins 0.000 claims 9
- 210000005259 peripheral blood Anatomy 0.000 claims 8
- 239000011886 peripheral blood Substances 0.000 claims 8
- 210000002381 plasma Anatomy 0.000 claims 4
- 102000004127 Cytokines Human genes 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 3
- 230000000770 proinflammatory effect Effects 0.000 claims 3
- 102000001400 Tryptase Human genes 0.000 claims 2
- 108060005989 Tryptase Proteins 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000005847 immunogenicity Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000002093 peripheral effect Effects 0.000 claims 2
- 238000004448 titration Methods 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 208000003084 Graves Ophthalmopathy Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 102100037850 Interferon gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 108090000174 Interleukin-10 Proteins 0.000 claims 1
- 102000003814 Interleukin-10 Human genes 0.000 claims 1
- 102000000588 Interleukin-2 Human genes 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 102000004889 Interleukin-6 Human genes 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 229940035676 analgesics Drugs 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- 230000003474 anti-emetic effect Effects 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002111 antiemetic agent Substances 0.000 claims 1
- 229940125683 antiemetic agent Drugs 0.000 claims 1
- 229940125715 antihistaminic agent Drugs 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 210000003289 regulatory T cell Anatomy 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 206010043778 thyroiditis Diseases 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25348209P | 2009-10-20 | 2009-10-20 | |
| US61/253,482 | 2009-10-20 | ||
| PCT/US2010/053438 WO2011050106A2 (en) | 2009-10-20 | 2010-10-20 | Anti-cd3 antibody dosing in autoimmune disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013508392A JP2013508392A (ja) | 2013-03-07 |
| JP2013508392A5 true JP2013508392A5 (https=) | 2013-12-05 |
Family
ID=43900947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012535347A Pending JP2013508392A (ja) | 2009-10-20 | 2010-10-20 | 自己免疫疾患における抗ｃｄ３抗体の投薬 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20120269826A1 (https=) |
| EP (1) | EP2490714A4 (https=) |
| JP (1) | JP2013508392A (https=) |
| CA (1) | CA2778334A1 (https=) |
| WO (1) | WO2011050106A2 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS67768B1 (sr) | 2010-11-30 | 2026-03-31 | Chugai Pharmaceutical Co Ltd | Terapijski agens koji indukuje citotoksičnost |
| GB201305714D0 (en) * | 2013-03-28 | 2013-05-15 | Ucl Business Plc | Method |
| CN118440206A (zh) | 2014-04-07 | 2024-08-06 | 中外制药株式会社 | 免疫活化抗原结合分子 |
| EP3144388B1 (en) * | 2014-05-13 | 2020-07-01 | Chugai Seiyaku Kabushiki Kaisha | T cell-redirecting antigen-binding molecule for cells having immunosuppression function |
| BR112016030740A2 (pt) | 2014-07-01 | 2018-02-20 | Pfizer Inc. | diacorpos heterodiméricos biespecíficos e seus usos |
| WO2017086419A1 (ja) | 2015-11-18 | 2017-05-26 | 中外製薬株式会社 | 液性免疫応答の増強方法 |
| US11660340B2 (en) | 2015-11-18 | 2023-05-30 | Chugai Seiyaku Kabushiki Kaisha | Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function |
| IL264502B2 (en) * | 2016-08-29 | 2023-09-01 | Tiziana Life Sciences Plc | Anti-cd3 antibody formulations |
| US10610104B2 (en) | 2016-12-07 | 2020-04-07 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
| US20210138213A1 (en) | 2017-03-30 | 2021-05-13 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
| WO2019246312A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
| US12227565B2 (en) | 2018-06-20 | 2025-02-18 | Biora Therapeutics, Inc. | Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine |
| US20220249814A1 (en) | 2018-11-19 | 2022-08-11 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
| MX2021012263A (es) * | 2019-04-10 | 2022-01-06 | Macrogenics Inc | Regimenes de dosificacion de diacuerpos cd123 x cd3 biespecificos en el tratamiento de neoplasias hematologicas. |
| IL322315A (en) | 2019-05-14 | 2025-09-01 | Provention Bio Inc | Methods and preparations for preventing type 1 diabetes |
| CN121197633A (zh) | 2019-12-13 | 2025-12-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| AU2021287998B2 (en) | 2020-06-11 | 2026-03-12 | Benaroya Research Institute At Virginia Mason | Methods and compositions for preventing type 1 diabetes |
| US12565529B2 (en) | 2021-05-24 | 2026-03-03 | Provention Bio, Inc. | Methods for treating type 1 diabetes |
| WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| EP4472646A1 (en) | 2022-02-01 | 2024-12-11 | Sana Biotechnology, Inc. | Cd3-targeted lentiviral vectors and uses thereof |
| US20250222027A1 (en) | 2022-04-01 | 2025-07-10 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
| US20260055146A1 (en) | 2022-08-24 | 2026-02-26 | Sana Biotechnology, Inc. | Delivery of heterologous proteins |
| WO2024119157A1 (en) | 2022-12-02 | 2024-06-06 | Sana Biotechnology, Inc. | Lipid particles with cofusogens and methods of producing and using the same |
| WO2024220597A2 (en) | 2023-04-18 | 2024-10-24 | Sana Biotechnology, Inc. | Digital droplet based assay for detecting replication competent lentiviral vector |
| KR20260016952A (ko) | 2023-05-23 | 2026-02-04 | 사나 바이오테크놀로지, 인크. | 탠덤 퓨소젠 및 관련 지질 입자 |
| WO2025184529A1 (en) | 2024-03-01 | 2025-09-04 | Sana Biotechnology, Inc. | Viral particles with fusogen display and related compositions and methods |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2380127A (en) * | 2001-09-26 | 2003-04-02 | Isis Innovation | Treatment of chronic joint inflammation |
| WO2005076965A2 (en) * | 2004-02-04 | 2005-08-25 | The Trustees Of Columbia University In The City Of New York | Anti-cd3 and antigen-specific immunotherapy to treat autoimmunity |
| AU2006267090B2 (en) * | 2005-07-11 | 2013-03-07 | Provention Bio, Inc. | Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity |
| AR057807A1 (es) * | 2005-09-12 | 2007-12-19 | Novimmune Sa | Formulaciones de anticuerpo anti-cd3 |
| JP2009539841A (ja) * | 2006-06-06 | 2009-11-19 | トラークス，インコーポレイテッド | 自己免疫疾患の治療における抗ｃｄ３抗体の投与 |
| SG10201504662WA (en) * | 2006-06-14 | 2015-07-30 | Macrogenics Inc | Methods For The Treatment Of Autoimmune Disorders Using Immunosuppressive Monoclonal Antibodies With Reduced Toxicity |
-
2010
- 2010-10-20 JP JP2012535347A patent/JP2013508392A/ja active Pending
- 2010-10-20 US US13/502,618 patent/US20120269826A1/en not_active Abandoned
- 2010-10-20 EP EP10825629.8A patent/EP2490714A4/en not_active Withdrawn
- 2010-10-20 CA CA2778334A patent/CA2778334A1/en not_active Abandoned
- 2010-10-20 WO PCT/US2010/053438 patent/WO2011050106A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013508392A5 (https=) | ||
| Kuhn et al. | Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside | |
| Hoffman | Therapy of autoinflammatory syndromes | |
| EP2637670B2 (en) | Prevention of adverse effects caused by cd3 specific binding domains | |
| JP2017523187A5 (https=) | ||
| JP2009500457A5 (https=) | ||
| JP2014533279A5 (https=) | ||
| JP2009539841A5 (https=) | ||
| JP2024129139A (ja) | ベンラリツマブを使用して喘息の増悪率を低減する方法 | |
| JP2005506331A5 (https=) | ||
| JP2020002172A5 (https=) | ||
| JP2009544761A5 (https=) | ||
| JP2010229134A5 (https=) | ||
| JP2009518441A5 (https=) | ||
| AU2023210647A1 (en) | Antibodies Neutralizing GM-CSF For Use In The Treatment Of Rheumatoid Arthritis Or As Analgesics | |
| JP2019526528A5 (https=) | ||
| JP2012102122A5 (https=) | ||
| JP2014500278A5 (https=) | ||
| JP2022513421A5 (https=) | ||
| JP2018538309A5 (https=) | ||
| EP3976193A1 (en) | Dosing of bispecific t cell engager | |
| JP2017520562A5 (https=) | ||
| JP2009538916A5 (https=) | ||
| JP2013508391A5 (https=) | ||
| Bannerji et al. | Safety and preliminary clinical activity of REGN1979, an anti-CD20 x anti-CD3 bispecific antibody, in patients with B-NHL previously treated with CD20-directed antibody therapy |